Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Transcription factors Stories

2013-09-30 14:04:37

Weizmann Institute researchers discover that a “standoff” between a mutated gene and its normal counterpart keeps certain cancer cells alive What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an internal “balance of terror” to keep going. When one version of a certain gene is mutated, it becomes a cancer-promoting...

2013-09-20 11:25:30

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene. "This is exciting because we've found what we believe to be a 'drugable target' here," says George Vasmatzis, Ph.D., a Mayo Clinic molecular...

2013-09-09 04:20:03

Discovery of RNA regulator could lead to a better understanding of diseases like cancer and influenzaSingapore, Sept 9, 2013 - (ACN Newswire) - Scientists at A*STAR's Genome Institute of Singapore (GIS), in collaboration with their counterparts from Canada, Hong Kong and US, have discovered a protein mediator SON plays a critical role in the health and proper functioning of human embryonic stem cells (hESCs). This finding was reported on 8th September 2013 in the...

2013-09-03 08:28:36

CAMBRIDGE, Mass., Sept. 3, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/310,157 "SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS" with claims covering the novel compound EPZ-5676. Epizyme's EPZ-5676 is a...

2013-09-02 16:20:25

CLEVELAND, Sept. 2, 2013 /PRNewswire-USNewswire/ -- The idea that men and women are fundamentally different from each other is widely accepted. And throughout the world, this has created distinct ideas about which social and physical characteristics are necessary in each gender to maintain healthy human development. However, social revolutions throughout the last century have challenged traditional ideas about not only which traits are normal and necessary for survival, but also how...

2013-08-16 08:23:55

Small Molecule Inhibitor of the DOT1L Histone Methyltransferase (HMT) designated for Acute Leukemias with MLL Rearrangements (MLL-r) CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for...

2013-08-07 16:27:52

RICHMOND, Calif., Aug. 7, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 9:10 am ET on Wednesday, August 14, 2013, at the 2013 Wedbush Life Sciences Management Access Conference which will be held in New York City. (Logo:...

2013-08-02 12:34:23

Weill Cornell scientists reveal how the protein works and how the drug gums it up, offering new hope for treatment of aggressive cancer Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, itself the...

2013-07-29 08:30:33

ORLANDO, Fla., July 29, 2013 /PRNewswire/ -- Pax8, a value-added distributor of unified cloud services, today announced its support of the Creating IT Futures Foundation, the philanthropic arm of CompTIA, through a program that will help the foundation grow as Pax8 grows. Starting today, Pax8 will donate $100 to the foundation on behalf of each new CompTIA-affiliated channel partner who joins the Pax8 Partner Program and creates its first billable customer account. Pax8 will also...

2013-07-23 11:45:23

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found. The discovery, described in a study to be published July 23 in eLife, may help explain how anti-inflammatory steroid drugs work. It also could someday lead to entirely new classes of anti-inflammatory treatments without some of steroids' damaging side effects. Chronic inflammation plays a role in cancer and in autoimmune, cardiovascular and...